
The phase III study found improved survival and slower disease progression with Roche’s investigational drug than with two existing treatments.
Roche said its investigational drug divarasib extended median overall survival to 17.7 months in a phase III trial of people with previously treated KRAS G12C-mutated lung cancer. The control group, which received sotorasib or adagrasib, had median overall survival of 12 months.
The study found a 44% lower risk of death with divarasib than with the control treatments. Divarasib also reduced the risk of disease progression or death by 42%, Roche said. Median progression-free survival was 9.8 months with divarasib and 5.7 months in the control group.
The confirmed response rate was 58% for divarasib and 32% for the control treatments. Roche said no new safety signals were observed. Treatment-related side effects led to discontinuation in 4.8% of divarasib patients, compared with 11.7% in the control group.
The results were presented at the 2026 European Society for Medical Oncology Congress and published in The New England Journal of Medicine. Roche said it is working with health authorities on the drug; divarasib remains investigational.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.